Summary

Atrial fibrillation (AF) guidelines recommend identical treatments for stroke prevention for all types of AF (permanent, persistent, paroxysmal), based on known risk factors for stroke. This article discusses the results of a secondary analysis of the Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation [ARISTOTLE; NCT00412984] trial, comparing rates of stroke or systemic embolism, bleeding, and mortality by AF type and treatment group.